Jun 7, 2024, 14:45
Manni Mohyuddin on DREAMM-7
Manni Mohyuddin shared on X/Twitter:
“In DREAMM-7 (bela/bort/dex vs dara/bort/dex).
- Only 34% of pts len refractory.
- POLLUX trial showed PFS of 45 months with dara/len/dex
- Would bela/velcade/dex (PFS=37 mo) beat DRd for len sensitive patients?
Answer is clear:
If len/dara sensitive at relapse, use dara/len/dex!
I do not think we will get such results with Bela/bortezomib/dex in a US population that is increasing both Dara and Len refractory at first relapse.
PFS will likely be very modest.
Some food for a (controversial thought). How much PFS2 do we sacrifice with our current approach to treating myeloma?”
Source: Manni Mohyuddin/X
Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.
Aug 14, 2024, 03:41